Novavax and Serum Institute filed for Emergency Use Authorization of Novavax’ COVID-19 vaccine in South Africa
On Jan. 10, 2022, Novavax and Serum Institute of India announced a regulatory submission to the South African…
-
-
Biden-Harris administration required insurance and group health plans to cover cost of at-home COVID-19 tests
On Jan. 10, 2022, the Biden-Harris Administration announced it was requiring insurance companies and group health plans to…
-
DoD awarded contract to Revival Health to purchase COVID-19 Antigen OTC kits in support of POTUS’ 500 million free at-home COVID-19 rests
On Jan. 7, 2022, the Department of Defense, in coordination with the U.S. Department of Health and Human…
-
COVID-19 | FDA | Life Science History | NIH
NRx Pharmac submited EUA Application to US FDA for ZYESAMIﾮ (aviptadil) to treat patients at risk of death from COVID-19
On Jan 5, 2022, NRx Pharmaceuticals announced that it had submitted an application for Emergency Use Authorization (EUA)…
-
Humanigen announced target enrollment in phase 2/3 ACTIV-5/BET-B trial of Lenzilumab for treatment of COVID-19 was met
On Jan. 5, 2021, Humanigen announced that target enrollment in the Phase 2/3 ACTIV-5/BET-B study had been achieved….
-
Pfizer and BioNTech signed global collaboration agreement to develop first mRNA-based shingles vaccine
On Jan. 5, 2022, Pfizer and BioNTech announced a new research, development and commercialization collaboration to develop a…
-
Pfizer provided U.S. Government with additional 10 million treatment courses of oral therapy to help combat COVID-19
On Jan. 4, 2022, Pfizer announced that the U.S. government had committed to purchasing an additional 10 million…
-
Pfizer and BioNTech received U.S. FDA EUA of COVID-19 vaccine booster for individuals 12 years of age and older
On Jan. 3, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration had expanded the…
-
Amyris and Immunitybio completed joint venture for next generation Covid-19 RNA vaccine
On Jan. 3, 2022, Amyris and ImmunityBio announced the completion of a previously announced joint venture agreement to…
-
Lenzilumab treatment response in hospitalized COVID-19 patients correlated with C-Reactive protein levels
On Jan. 3, 2021, Humanigen announced that a manuscript detailing the results of an analysis of CRP levels…
-
Johnson & Johnson COVID-19 vaccine demonstrated 85 percent effectiveness against hospitalization in South Africa when Omicron was dominant
On Dec. 30, 2021, Johnson & Johnson announced preliminary results from the South African Phase 3b Sisonke study…
-
NRx Pharma filed Breakthrough Therapy Designation request for ZYESAMIﾮ (aviptadil) in patients at risk of COVID-19 death
On Dec. 29, 2021, NRx Pharmaceuticals announced that it hds filed a new Breakthrough Therapy Designation (BTD) request…
-
U.S. DoD awarded $136.7 million to MilliporeSigma for domestic production capacity of COVID-19 point-of-care tests parts
On Dec. 29, 2021, the Department of Defense (DoD), on behalf of and in coordination with the U.S….
-
COVID-19 vaccine developed by Biological E using Dynavax’s CpG 1018 adjuvant received India DCGI approval for emergency use
On Dec. 28, 2021, Dynavax announced that Biological E had reported that CORBEVAXﾙ, their COVID-19 vaccine which contains…
-
Biotechnology | COVID-19 | Disease | Genomics
PacBio’s HiFiViral Surveillance Kit Performance not impacted by Omicron mutations
On Dec. 28, 2021, Pacific Biosciences announced that its new HiFiViral SARS-CoV-2 solution had successfully sequenced and captured…
-
Development of WRAI’s pan-coronavirus vaccine showed promise
On Dec. 28, 2021, researchers at the Walter Reed Army Institute of Research in Silver Spring, Maryland announced…
-
Novavax and Serum Institute of India received Emergency Use Authorization for COVID-19 vaccine in India
On Dec. 28, 2021, Novavax and Serum Institute of India announced that the Drugs Controller General of India…
-
Sorrento announced COVISTIX COVID-19 virus rapid antigen detection test detected the Omicron variant
On Dec. 27, 2021, Sorrento Therapeutics announced that initial testing of COVISTIX on recombinant N proteins demonstrated its…
-
Moderna announced Switzerland exercised option to purchase seven million additional doses of COVID-19 booster vaccine
On Dec. 27, 2021, Moderna announced that the Swiss Federal Government had exercised its option to purchase an…
-
Moderna announced supply agreement with South Korea for additional 20 million doses of COVID-19 vaccine
On Dec. 27, 2021, Moderna announced a revised supply agreement with the government of South Korea for 20…
-
FDA authorized COVID-19 Over-the-Counter test based on data from NIH Independent Test Assessment Program
On Dec. 27, 2021, the U.S. Food and Drug Administration authorized an over-the-counter (OTC) COVID-19 antigen test, the…
-
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | FDA | Life Science History | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
COVID-19 heroes & Remembrance
Our Heroes and Remembrance illustration has Maurice Ralph Hilleman and John Enders, pioneering developers of common vaccines, and…
-
Roche COVID-19 at-home test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States
On Dec. 24, 2021, Roche announced that the U.S. Food and Drug Administration had granted Emergency Use Authorization…
-
Merck and Ridgeback’s molnupiravir, an investigational oral antiviral COVID-19 treatment, received special approval for emergency in Japan
On Dec. 24, 2021, Merck and Ridgeback Biotherapeutics announced that Japanﾒs Ministry of Health, Labor and Welfare had…
-
Biotechnology | COVID-19 | FDA | Medicine | Pharmaceutical | Therapeutics
Merck and Ridgeback’s molnupiravir received U.S. FDA EUA for treatment of high-risk adults with COVID-19
On Dec. 23, 2021, Merck and Ridgeback Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) had…
-
Novavax and SK bioscience announed expanded manufacturing agreement
On Dec. 23, 2021, Novavax and SK bioscience announced the expansion of the companies’ collaboration and license agreements…
-
OPKO Health announced topline results from phase 2 trial evaluating RAYALDEE to treat symptomatic COVID-19 outpatients
On Dec. 23, 2021, OPKO announced preliminary topline results from its Phase 2 trial with RAYALDEEﾮ to treat…
-
Pfizer and BioNTech submit updated longer-term follow-up data of COMIRNATY in adolescents to EMA
On Dec. 23, 2021, Pfizer and BioNTech announced that they had submitted longer-term follow-up data from the companiesﾒ…
-
Merck and Ridgeback announced U.K. Government to purchase additional 1.75 million courses of molnupiravir
On Dec. 22, 2021, Merck and Ridgeback Biotherapeutics announced that the United Kingdom Government agreed to purchase an…
-
Novavax announced initial Omicron cross-reactivity data from COVID-19 vaccine booster and adolescent studies
On Dec. 22, 2021, Novavax announced initial data evaluating the immune response of its COVID-19 vaccine, NVX-CoV2373, against…
